RaySearch Laboratories AB Class B (DE:27R)
FRANKFURT:27R
27R Stock Chart & Stats
€19.54
-€0.10(-0.53%)
At close: 4:00 PM EST
€19.54
-€0.10(-0.53%)
Day’s Range― - ―
52-Week Range€15.74 - €32.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€712.75M
Enterprise Value€7.47B
Total Cash (Recent Filing)€439.30M
Total Debt (Recent Filing)€377.30M
Price to Earnings (P/E)33.5
Beta0.98
Next Earnings
Aug 13, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.54
Shares Outstanding30,799,536
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.87
Price to Book (P/B)7.93
Price to Sales (P/S)5.81
P/FCF Ratio21.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.75
Revenue Forecast (FY)€133.78M
Bulls Say, Bears Say
Bulls Say
Strong Profitability And ReturnsSustained high margins and strong ROE create durable internal funding for R&D, product enhancements and customer support. Consistent profitability also cushions cyclicality in sales, supports dividend/payout capacity and enables reinvestment without heavy reliance on external capital.
Recurring, Software-based Revenue ModelA software licensing and maintenance model drives predictable, high-margin recurring revenue and strong customer stickiness given clinical integration needs. This structural revenue mix supports multi-year visibility, lower churn and scalable margins versus one-time sales.
Solid Free Cash Flow GenerationConsistent positive and growing free cash flow strengthens the firm's ability to service debt, fund product roadmap, and return capital. Reliable FCF reduces refinancing risk and underpins strategic investments even if revenue growth moderates.
Bears Say
Weakening Revenue MomentumA small but persistent decline in TTM revenue signals potential demand headwinds or market saturation in key segments. If sustained, slower top-line growth can pressure operating leverage, limit reinvestment capacity, and reduce headroom to absorb competitive pricing or sales investments.
Uneven Cash ConversionMaterial gaps between accounting profits and cash generation increase sensitivity to working capital swings and timing. Persistent sub-par conversion can constrain funding for capex, M&A or shareholder returns and raises reliance on steady profitability to meet obligations.
Meaningful Absolute Debt BurdenAlthough leverage ratios are controlled, significant absolute debt requires consistent cash generation to service interest and reduce principal. In a slower growth environment, this can limit strategic flexibility and raise refinancing or interest-rate sensitivity risks over the medium term.
RaySearch Laboratories AB News
27R FAQ
What was RaySearch Laboratories AB Class B’s price range in the past 12 months?
RaySearch Laboratories AB Class B lowest stock price was €15.74 and its highest was €32.70 in the past 12 months.
What is RaySearch Laboratories AB Class B’s market cap?
RaySearch Laboratories AB Class B’s market cap is €712.75M.
When is RaySearch Laboratories AB Class B’s upcoming earnings report date?
RaySearch Laboratories AB Class B’s upcoming earnings report date is Aug 13, 2026 which is in 67 days.
How were RaySearch Laboratories AB Class B’s earnings last quarter?
RaySearch Laboratories AB Class B released its earnings results on Apr 29, 2026. The company reported €0.142 earnings per share for the quarter, beating the consensus estimate of €0.135 by €0.007.
Is RaySearch Laboratories AB Class B overvalued?
According to Wall Street analysts RaySearch Laboratories AB Class B’s price is currently Overvalued.
Does RaySearch Laboratories AB Class B pay dividends?
RaySearch Laboratories AB Class B does not currently pay dividends.
What is RaySearch Laboratories AB Class B’s EPS estimate?
RaySearch Laboratories AB Class B’s EPS estimate is 0.15.
How many shares outstanding does RaySearch Laboratories AB Class B have?
RaySearch Laboratories AB Class B has 30,799,536 shares outstanding.
What happened to RaySearch Laboratories AB Class B’s price movement after its last earnings report?
RaySearch Laboratories AB Class B reported an EPS of €0.142 in its last earnings report, beating expectations of €0.135. Following the earnings report the stock price went down -5.751%.
Which hedge fund is a major shareholder of RaySearch Laboratories AB Class B?
Currently, no hedge funds are holding shares in DE:27R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaySearch Laboratories AB Class B
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
27R Company Deck
27R Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and commercial picture: record revenues, strong organic growth, improving profitability and cash position, significant clinical milestones and substantial AI adoption/use cases. Key negatives are material currency headwinds, a book-to-bill ratio below 1 and slower-than-desired traction for RayCare (partly tied to regulatory timing). Management expects margin improvement (target at least 25% for 2026) and a RayCare ramp in coming years, and has strengthened shareholder returns with a higher dividend and a 50% payout policy.View all DE:27R earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---